Skip to main
MNKD

MannKind (MNKD) Stock Forecast & Price Target

MannKind (MNKD) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 57%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

MannKind Corp's ongoing advancements in its orphan lung pipeline position the company for long-term diversification and growth, significantly enhancing its revenue potential. The management's targeted marketing strategies and educational campaigns are expected to boost uptake of their products, particularly Afrezza and Tyvaso DPI, across key therapeutic areas. Additionally, the company's efforts to secure approval for the Furoscix auto-injector could further solidify its standing as a valuable revenue driver, highlighting robust royalty income opportunities in pulmonary arterial hypertension and related indications.

Bears say

MannKind Corporation faces significant challenges following the announcement of a competing product to Furoscix, leading to a notable decline in stock price and raising concerns about the company's competitive positioning and market share. The potential for adverse trial outcomes or regulatory setbacks threatens to hinder the commercialization of its pipeline products, namely MNKD-102 and MNKD-201, as they aim to address unmet medical needs in lung diseases. Additionally, the presence of well-capitalized competitors with established products may further erode MannKind's market presence and limit pricing power, contributing to an overall negative outlook on the stock.

MannKind (MNKD) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 57% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MannKind (MNKD) Forecast

Analysts have given MannKind (MNKD) a Buy based on their latest research and market trends.

According to 7 analysts, MannKind (MNKD) has a Buy consensus rating as of Apr 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.93, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.93, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MannKind (MNKD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.